| Mean ± SD or count (%) | ||
Age (years) | 73.2 ± 9.1 | ||
| 40 - 49 | 8 (1.6%) | |
| 50 - 59 | 35 (7.0%) | |
| 60 - 69 | 107 (21.4%) | |
| 70 - 79 | 226 (45.3%) | |
| 80 - 89 | 115 (23.0%) | |
| 90 - 99 | 8 (1.6%) | |
Sex |
| ||
| Male | 268 (53.7%) | |
| Female | 231 (46.3%) | |
Race |
| ||
| Caucasian | 497 (99.6%) | |
| Asian | 1 (0.2%) | |
| Other | 1 (0.2%) | |
Disease duration (years) | 3.6 ± 3.7 | ||
| <1 | 60 (12.0%) | |
| 1 - 5 | 332 (66.5%) | |
| 6 - 10 | 82 (16.4%) | |
| 11 - 15 | 17 (3.4%) | |
| 16 - 20 | 6 (1.2%) | |
| 20 - 25 | 2 (0.4%) | |
Presence of motor fluctuations at baseline |
| ||
| No | 412 (82.6%) | |
| Yes | 87 (17.4%) | |
Antiparkinsonian treatment at baseline |
| ||
| No | 100 (20.0%) | |
| Yes | 399 (80.0%) | |
| L-dopa + benserazide | 144 (28.9%) | |
| LCE | 75 (15.0%) | |
| Ropinirole | 74 (14.8%) | |
| Pramipexole | 67 (13.4%) | |
| Rotigotine | 46 (9.2%) | |
| Selegiline | 56 (11.2%) | |
| Amantadine | 37 (7.4%) | |
| Procyclidine | 1 (0.2%) | |
| Biperiden | 4 (0.8%) | |
| Other | 42 (8.4%) | |